PTK2 and acute lymphoblastic leukemia: This study highlights WT161’s therapeutic potential in ALL, demonstrating its ability to inhibit PKA activity and disrupt the VLA-4/FAK pathway, thereby offering a promising novel strategy for ALL treatment.